The University of Chicago Header Logo

Connection

Lucy Godley to Leukemia, Myeloid, Acute

This is a "connection" page, showing publications Lucy Godley has written about Leukemia, Myeloid, Acute.
Connection Strength

6.433
  1. Germline mutations in MDS/AML predisposition disorders. Curr Opin Hematol. 2021 03 01; 28(2):86-93.
    View in: PubMed
    Score: 0.512
  2. Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Curr Hematol Malig Rep. 2018 12; 13(6):426-434.
    View in: PubMed
    Score: 0.438
  3. MBD4: guardian of the epigenetic galaxy. Blood. 2018 10 04; 132(14):1468-1469.
    View in: PubMed
    Score: 0.433
  4. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol. 2018 12; 31(4):373-378.
    View in: PubMed
    Score: 0.432
  5. Germline ETV6 mutations and predisposition to hematological malignancies. Int J Hematol. 2017 Aug; 106(2):189-195.
    View in: PubMed
    Score: 0.394
  6. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014 Oct; 51(4):306-21.
    View in: PubMed
    Score: 0.325
  7. On the origin of leukemic species. Cell Stem Cell. 2014 Apr 03; 14(4):421-2.
    View in: PubMed
    Score: 0.317
  8. Profiles in leukemia. N Engl J Med. 2012 Mar 22; 366(12):1152-3.
    View in: PubMed
    Score: 0.275
  9. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24.
    View in: PubMed
    Score: 0.257
  10. Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29.
    View in: PubMed
    Score: 0.214
  11. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials. 2007 May; 2(2):135-41.
    View in: PubMed
    Score: 0.196
  12. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.151
  13. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 06 02; 13(6):1478-1497.
    View in: PubMed
    Score: 0.150
  14. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023 02 02; 141(5):534-549.
    View in: PubMed
    Score: 0.146
  15. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.144
  16. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
    View in: PubMed
    Score: 0.143
  17. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007.
    View in: PubMed
    Score: 0.134
  18. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv. 2020 03 24; 4(6):1131-1144.
    View in: PubMed
    Score: 0.120
  19. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
    View in: PubMed
    Score: 0.119
  20. Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. Leuk Lymphoma. 2020 01; 61(1):246-247.
    View in: PubMed
    Score: 0.116
  21. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
    View in: PubMed
    Score: 0.103
  22. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.103
  23. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527.
    View in: PubMed
    Score: 0.100
  24. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 09; 58(9):1-7.
    View in: PubMed
    Score: 0.097
  25. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016 Feb 25; 127(8):1017-23.
    View in: PubMed
    Score: 0.089
  26. Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes. J Biol Chem. 2016 Feb 19; 291(8):4256-65.
    View in: PubMed
    Score: 0.089
  27. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood. 2015 Nov 26; 126(22):2484-90.
    View in: PubMed
    Score: 0.088
  28. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015 May 11; 27(5):658-70.
    View in: PubMed
    Score: 0.085
  29. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014 Dec 11; 9(5):1841-1855.
    View in: PubMed
    Score: 0.083
  30. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci. 2014 Mar; 1310:111-8.
    View in: PubMed
    Score: 0.078
  31. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma. 2013 Feb; 54(2):408-10.
    View in: PubMed
    Score: 0.070
  32. The histone code and treatments for acute myeloid leukemia. N Engl J Med. 2012 Mar 08; 366(10):960-1.
    View in: PubMed
    Score: 0.069
  33. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
    View in: PubMed
    Score: 0.064
  34. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011 Mar 24; 117(12):3294-301.
    View in: PubMed
    Score: 0.064
  35. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec 14; 18(6):553-67.
    View in: PubMed
    Score: 0.063
  36. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res. 2008 Apr 15; 14(8):2444-9.
    View in: PubMed
    Score: 0.052
  37. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.050
  38. TTID: A novel gene at 5q31 encoding a protein with titin-like features. Genomics. 1999 Sep 01; 60(2):226-33.
    View in: PubMed
    Score: 0.029
  39. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis. Blood. 2016 Mar 24; 127(12):1575-86.
    View in: PubMed
    Score: 0.022
  40. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.